Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis.

导出 OA

翻译打印收藏纠错

作者： Xin,Hu ^[1] ; Shuli,Qu ^[2] ; Xingxing,Yao ^[3] ; Chaoyun,Li ^[3] ; Yanjun,Liu ^[2] ; Jianye,Wang ^[4]

作者单位： 1Department of Pharmacy, Beijing Hospital, Beijing, China. ^[1] Real World Solutions, IQVIA, Shanghai, China. ^[2] 3Health Economics & Outcome Research, Sanofi, Shanghai, China. ^[3] 4Department of Urology, Beijing Hospital, No. 1 Dongdan Dahua Road, Dongcheng District, Beijing, 100730 China. ^[4]

关键词 Abiraterone Cost analysis Docetaxel Prostate cancer

DOI 10.1186/s12962-019-0193-4

PMID 31871432

发布时间 2024-07-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cost effectiveness and resource allocation

2019年17卷

27页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis.

Cost effectiveness and resource allocation

相似文献

Cost effectiveness and resource allocation

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis.

Cost effectiveness and resource allocation

相似文献

Cost effectiveness and resource allocation

相关期刊

检索历史清除